|
|
|
|
Agrium Inc. Q4 2009 Earnings Call Transcript
Agrium Inc.(AGU) Executives Mike Wilson - President & Chief Executive Officer Bruce Waterman - Chief Financial Officer Ron Wilkinson - Senior Vice President & President of Wholesale Business Unit Kevin Helash - Vice President of Marketing &...
|
|
|
Shoppers Drug Mart Target Cut To C$52 From C$56 By RBC SC.T
_ Shoppers Drug Mart Target Cut To C$52 From C$56 By RBC SC.T.
|
|
|
SIS RBC solution meets the stringent standards of Peer Review program
For the third consecutive year, the Healthcare Financial Management Association (HFMA) performed a rigorous assessment of SIS Rules-Based Charging (RBC), an automated charge capture solution by Surgical Information Systems, and determined that it meets...
|
|
|
Blood-freezing method allows for transplant of incompatible kidney
British doctors used a freezing method to filter out antibodies from a patient's blood so that she would be able to receive f- More - Bring Synergy into Your Strategic Planning The systems of the Leukotrap Synergy Platform - Leukotrap RC with RC2D Filter,...
|
|
|
Cincinnati Financial Corp. Q4 2009 Earnings Call Transcript
Marty Mullen - Chief Claims Officer Dennis McDaniel - Investor Relations Analysts Michael Phillips - Stifel Nicolaus Paul Newsome - Sandler ONeill & Partners Scott Heleniak - RBC Capital Markets Dan Schlemmer - Macquarie Presentation Operator Good...
|
|
|
Extendicare REIT Completes $86.3 Million Offering of Trust Units
MARKHAM, ONTARIO--(Marketwire - Feb.4, 2010) - Extendicare Real Estate Investment Trust ("Extendicare REIT" or the "REIT") (TSX: EXE-UN.TO) announced today that it has closed its previously announced offering of 9,228,750 trust units of the REIT (the "Trust...
|
|
|
Reduced Florida donations tied to recession
The blood banks in Florida have seen a decrease in blood donations since the recession started, even as the national blood su- More - Bring Synergy into Your Blood Supply With the Leukotrap RC System with RC2D Filter collect all your WB donations with one...
|
|
|
Qwest Energy 2010 Flow-Through Limited Partnership; $25,000,000 Preliminary Prospectus Filed
Qwest Investment Management Corp.is pleased to announce that on February 1, 2010, it filed a preliminary prospectus for the initial public offering of units of the Qwest Energy 2010 Flow-Through Limited Partnership (the 'Partnership'). Funds raised by the...
|
|
|
Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy
Stamp LK et al.The aim of this study was to define a therapeutic range of red blood cell (RBC) MTXGlun concentrations (where n refers to the number of glutamate groups), including threshold values for efficacy and adverse effects in patients receiving...
|
|
|
Toronto stocks may gain on commodity price rises
Investors may look past overseas markets, which were stung by woes about Greece's government debt and China inflation jitters, and focus on the U.S.factory data. stock index futures also pointed to a higher open. The Toronto Stock Exchange's S&P/TSX...
|
|
|
ImmunoGen, Inc. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript
ImmunoGen, Inc.(IMGN) F2Q10 (Qtr End 12/31/09) Earnings Call Transcript January 28, 2010 4:30 pm ET Executives Carol Hausner Executive Director, IR & Corporate Communications Dan Junius President & CEO Greg Perry SVP & CFO Analysts Joel Sendek...
|
|
|
Elizabeth Arden, Inc. Q2 2010 Earnings Call Transcript
Joel Ronkin - EVP North America Fragrances Steve Smith - EVP & CFO Marcey Becker - SVP of Finance and Business Development Analysts Joe Altobello - CIBC World Markets Arnie Ursaner - CJS Securities Alice Longley - Buckingham Research Bill Chappell -...
|
|
|
Roche and RBC named most unscrupulous firms
The Basel-based pharmaceutical giant Roche and the Royal Bank of Canada (RBC) are this years recipients of the Public Eye Award in Davos.Presented on the sidelines of the World Economic Forum (WEF) meeting in the Swiss resort, the annual awards are...
|
|
|
RBC Capital Initiates Coverage on Human Genome Sciences (HGSI) with an Outperform
RBC Capital initiates coverage on Human Genome Sciences (Nasdaq: HGSI) with an Outperform rating.Price target $38. RBC Capital Initiates Coverage on Human Genome Sciences (HGSI) with an Outperform.
|
|
|
Human Genome Sciences (HGSI) NewsBite - HGSI Gets Outperform Rating From RBC
Human Genome Sciences (NASDAQ: HGSI) opened at $27.92.So far today, the stock has hit a low of $27.41 and a high of $27.95. HGSI is now trading at $27.67, up $0.15 (0.55%). Over the last 52 weeks the stock has ranged from a low of $.45 to a high of $32...
|
|
|
Human Genome Sciences (HGSI) Gets Outperform Rating From RBC
Human Genome Sciences (NASDAQ: HGSI) opened at $27.92.So far today, the stock has hit a low of $27.41 and a high of $27.95. HGSI is now trading at $27.67, up $0.15 (0.55%). Over the last 52 weeks the stock has ranged from a low of $.45 to a high of $32...
|
|
|
Human Genome Sciences (HGSI) Gets Outperform
Human Genome Sciences (NASDAQ: HGSI) opened at $27.92.So far today, the stock has hit a low of $27.41 and a high of $27.95. HGSI is now trading at $27.67, up $0.15 (0.55%). Over the last 52 weeks the stock has ranged from a low of $.45 to a high of $32...
|
|
|
Abbott Laboratories Q4 2009 Earnings Call Transcript
Abbott Laboratories (ABT) Executives John Thomas VP, IR Miles White Chairman and CEO Tom Freyman EVP, Finance and CFO Analysts Mike Weinstein JPMC Jami Rubin Goldman Sachs Glenn Novarro RBC Capital Markets David Lewis Morgan Stanley Sara Michelmore Cowen...
|
|
|
Human Genome Sciences (HGSI) NewsBite - HGSI Gets Outperform Rati...
Company: Human Genome Sciences, Inc.(HGSI) Human Genome Sciences (NASDAQ: HGSI) opened at $27.92. So far today, the stock has hit a low of $27.41 and a high of $27.95. HGSI is now trading at $27.67, up $0.15 (0.55%). Over the last 52 weeks the stock...
|
|
|
Human Genome Sciences (HGSI) NewsBite - HGSI Gets Outperform Rati...
Company: Human Genome Sciences, Inc.(HGSI) Human Genome Sciences (NASDAQ: HGSI) opened at $27.92. So far today, the stock has hit a low of $27.41 and a high of $27.95. HGSI is now trading at $27.67, up $0.15 (0.55%). Over the last 52 weeks the stock...
|
|
|
Gilead Sciences, Inc. Q4 2009 Earnings Call Transcript
Gilead Sciences, Inc.(GILD) Executives Susan Hubbard VP, IR John Martin Chairman and CEO Robin Washington SVP and CFO Kevin Young EVP, Commercial Operations Norbert Bischofberger EVP, R&D and Chief Scientific Officer John Milligan President and COO...
|
|
|
Johnson & Johnson Q4 2009 Earnings Call Transcript
8:30 am ET Executives Louise Mehrotra VP, IR Bill Weldon Chairman and CEO Dominic Caruso VP, Finance and CFO Analysts Rick Wise Leerink Swann David Lewis Morgan Stanley Jami Rubin Goldman Sachs Michael Weinstein J.P.Morgan Matt Dodds Citigroup Tao Levy...
|
|
|
Amgen, Inc. Q4 2009 Earnings Call Transcript
5:00 pm ET Executives Kevin Sharer - Chairman & Chief Executive Officer Bob Bradway - Chief Financial Officer George Morrow - Executive Vice President of Global Commercial Operations Roger Perlmutter - Executive Vice President of Research & Development...
|
|
|
Synthetic red blood cells mimic the real thing
SANTA BARBARA, Calif.-Scientists at University of California, Santa Barbara (UCSB) and the have collaborated to develop synthetic particles that closely mimic the characteristics and key functions of natural red blood cells, including softness, flexibility and...
|
|
|
Curis prices registered direct offering at $2.52 per unit
(Datamonitor via COMTEX) -- Curis, a drug development company, has priced a registered direct offering of 6.45 million units, at a price of $2.52 per unit, for gross proceeds of $16.25 million before deducting placement agents' fees and estimated offering...
|
